News | October 26, 2022
Novartis maintains growth momentum; Confirms FY’22 Group guidance
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Pluvicto and Scemblix launches are progressing well and we are awaiting data in earlier lines of therapy.
Around 62% of the revenues came from the domestic market and 38% from the exports market for Q2 FY23 for a standalone business
Revenue from operations up 26% to Rs. 768 crores
Government Ayurveda College & Hospital will include an infrastructure for the College and a 100 bedded hospital, hostel block for students and staff quarters.
The move will add new global talent to Cytel’s Strategic Consulting group
The award was presented to Biocon Foundation as a mark of recognition of various projects undertaken during the year for reducing the environmental impact on cities
The reduction in force will result in financial savings of approximately $50 million annually beginning in 2023
The two overhead tanks commissioned at a cost of Rs 57 lakh will be maintained by the village panchayats.
Construction is now underway with the facility scheduled to be operational by 2025
Our strategy to drive therapy and brand-focused expansion will continue to show results, especially in the domestic business.
Subscribe To Our Newsletter & Stay Updated
